SCHEMBL22200825

SCHEMBL22200825

Cc1nc(NSCc2ccc(F)cc2)ccc1-c1nc2cnc(N)nc2n(C(C)C)c1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 11/20 0.36
CYP3A4 P08684 11/20 0.36
USP2 O75604 10/20 0.36
ALDH1A1 P00352 9/20 0.36
HSD17B10 Q99714 8/20 0.36
CYP2C19 P33261 7/20 0.36
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
CLK4 Q9HAZ1 1/20 0.36
RORC P51449 2/20 0.36
CYP2C9 P11712 8/20 0.35
TSHR P16473 6/20 0.35
HIF1A Q16665 5/20 0.35
HPGD P15428 2/20 0.35
MAPK1 P28482 2/20 0.35
MTOR P42345 3/20 0.35
CASP1 P29466 4/20 0.34
CASP7 P55210 4/20 0.34
GLA P06280 1/20 0.33
CYP2D6 P10635 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25035392 0.85 ERN1 (0.41) CYP1A2CYP3A4USP2ALDH1A1HSD17B10
SCHEMBL22200792 0.84 MTOR (0.35) RORCMTOR
SCHEMBL22200612 0.83 RORC (0.35) CYP1A2CYP3A4USP2ALDH1A1HSD17B10
SCHEMBL22200594 0.83 RORC (0.34) CYP1A2CYP3A4USP2ALDH1A1HSD17B10
SCHEMBL22200788 0.81 USP2 (0.40) CYP1A2CYP3A4USP2ALDH1A1HSD17B10
SCHEMBL22200653 0.81 MTOR (0.38) ALDH1A1HSD17B10RORCHPGDMTOR
SCHEMBL22200603 0.80 ERN1 (0.43) CYP1A2CYP3A4USP2ALDH1A1HSD17B10
SCHEMBL22200721 0.79 RORC (0.35) CYP1A2CYP3A4USP2ALDH1A1HSD17B10
SCHEMBL22200799 0.79 RORC (0.34) RORCMTOR
SCHEMBL22200634 0.78 MTOR (0.41) CYP1A2CYP3A4USP2ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020142612-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. GENENTECH, INC. (US) 2020-07-09 WO disclosed